Merck (MRK) finalises $6.7 billion Terns Pharmaceuticals acquisition, bolsters pipeline
Merck & Co. finalised its $6.7 billion cash acquisition of Terns Pharmaceuticals on Tuesday, May 5, 2026. The transaction, which expands Merck's pharmaceutical pipeline, concluded following the expiration of the Hart-Scott-Rodino Act waiting period. This development represents a strategic move to bolster the United States-based company's drug development capabilities.
Acquisition Details
The all-cash deal, reported by Benzinga and OTC Markets, adds Terns' assets to Merck's portfolio. This marks a significant pipeline expansion for Merck, with no other major corporate developments, such as earnings updates or new partnerships, occurring in the 18 hours preceding this report. Merck had released its first-quarter earnings on April 30.
Merck & Co. shares are trading at $112.04 as of 2026-05-08, reflecting a 0.2% decline from yesterday's close of $112.30. The market's reaction to the acquisition has been subdued, with the stock showing minimal intraday movement.
Why a Big Acquisition Can Lead to a Small Market Move
Merck & Co. is a global pharmaceutical powerhouse, dedicated to discovering, developing, manufacturing, and selling a wide range of prescription medicines, vaccines, and animal health products. Their customers span patients, healthcare providers, and veterinarians worldwide, with revenue primarily generated from the sales of these often patented and high-margin pharmaceutical innovations.
Today's minimal movement in Merck's share price stems from the market's subdued reaction to its $6.7 billion cash acquisition of Terns Pharmaceuticals, which was finalised on Tuesday, May 5, 2026. While a multi-billion dollar deal to expand Merck's drug development pipeline might seem like significant news, the market often anticipates such strategic moves. The completion of the Hart-Scott-Rodino Act waiting period, mentioned in the recap, indicates that this transaction was in the works and likely priced into the stock well before its official close, leaving little new information for investors to react to today.
Consequently, Merck shares are trading down by just 0.2% today, currently at $112.04, a slight dip from yesterday's close of $112.30. This small shift reflects the market's already-formed opinion on the acquisition.
Think of it like a highly anticipated movie sequel. If all the major plot points and casting details have been leaked and discussed for months before the release, the actual opening day might not cause a huge stir in public opinion. The excitement, or lack thereof, has already been factored in.
Merck & Co.
Merck & Co., Inc. (MRK) operates as a global healthcare enterprise, specialising in pharmaceutical and animal health solutions. Its Pharmaceutical division develops human health products spanning oncology, immunology, neuroscience, and cardiovascular conditions, alongside a portfolio of vaccines for paediatric, adolescent, and adult populations. The Animal Health segment focuses on veterinary pharmaceuticals, vaccines, and health management services, including digital identification and monitoring tools. Merck serves a diverse client base, from drug wholesalers and hospitals to managed healthcare providers, physicians, veterinarians, and animal producers. The firm also engages in strategic collaborations, including partnerships with AstraZeneca PLC and Gilead Sciences, Inc. for HIV treatments. Established in 1891, Merck & Co., Inc. is headquartered in Kenilworth, New Jersey.